Pramocaine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Pramocaine: From Topical Skin and Anorectal Conditions to Papillary Conjunctivitis
One-Sentence Summary
Pramocaine (pramoxine) is a topical surface anaesthetic, originally used for skin irritation, itch and anorectal conditions such as haemorrhoids and proctitis. The TxGNN model predicts it may be useful for papillary conjunctivitis, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dermatitis, tinea infections, haemorrhoids, proctitis, burns, otitis externa (from the knowledge graph; no approved indication text is available for the UK product) |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L5 |
| UK Market Status | Marketed |
| Number of Marketing Authorisations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pramocaine is generally understood to be a topical surface anaesthetic that blocks voltage-gated sodium channels in sensory nerve endings, and it is used to relieve itch and discomfort. This general description has not been verified against the compiled data.
The suggested link to papillary conjunctivitis is symptomatic: itch is a hallmark of allergic and contact-lens-related papillary conjunctivitis, so a local anaesthetic with antipruritic action could in theory ease ocular itching and discomfort. This is speculative. The high TxGNN score is a computational output only and is not backed by clinical or literature evidence.
There is also an important concern. Topical anaesthetics can cause corneal toxicity with repeated use, and pramocaine formulations are not designed or approved for ophthalmic use. The route of administration is therefore a major unresolved issue.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 0107020J0AAADAD (BNF-style product code; not a PL number) | Hydrocort/Pramocaine Foam Enema (40D) | Not specified | Not specified |
The product is a hydrocortisone and pramocaine combination foam enema, which falls within the BNF section on rectal corticosteroid preparations. This is a rectal product, not an ophthalmic one.
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): The knowledge graph links the drug to potential contraindications or cautions in conditions including hypertension, kidney disease, herpes simplex keratitis, varicella zoster infection, fungal infections and dermatophytosis, other infectious diseases, diabetes mellitus and diabetic ketoacidosis, open-angle glaucoma, osteoporosis, adrenocortical insufficiency, hypothyroidism, psychotic and mental disorders, contact dermatitis, benign prostatic hyperplasia, coronary artery disease and sudden cardiac arrest. Many of these are likely to reflect the corticosteroid component of the combination product rather than pramocaine itself. Several (herpes simplex keratitis, open-angle glaucoma, infections) are particularly relevant to any ocular use.
- Ocular safety: Repeated use of topical anaesthetics on the eye can cause corneal toxicity.
No drug interaction data were found.
Please refer to the SmPC and BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (Evidence Level L5), with no trials or publications. The available UK product is a rectal combination with a corticosteroid, and ocular use raises a real corneal safety concern.
To proceed, the following is needed:
- Mechanism of action data for pramocaine
- Published or registered evidence for ocular use, or a rationale for an ophthalmic formulation
- Route and formulation feasibility assessment, as the current UK product is not ophthalmic
- Ocular safety (corneal toxicity) assessment
- Approved indication and SmPC safety information for the UK product
- Comparison against established treatments for papillary conjunctivitis (for example, antihistamine or mast cell stabiliser eye drops)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.